A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis.

[1]  J. Zic.  The treatment of cutaneous T‐cell lymphoma with photopheresis , 2003, Dermatologic therapy.

[2]  T. Alcindor,et al.  Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis , 2002, Bone Marrow Transplantation.

[3]  D. Margolis,et al.  Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. , 2001, Archives of dermatology.

[4]  P. Bossuyt,et al.  Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). , 1999, Journal of the American Academy of Dermatology.

[5]  W. Macey,et al.  Photopheresis: clinical applications and mechanism of action. , 1999, The journal of investigative dermatology. Symposium proceedings.

[6]  W. Macey,et al.  Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. , 1996, Journal of the American Academy of Dermatology.

[7]  Y. Shyr,et al.  Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. , 1996, Journal of the American Academy of Dermatology.

[8]  J. Pope,et al.  Treatment of systemic sclerosis. , 1996, Rheumatic diseases clinics of North America.

[9]  B. White,et al.  Immunopathogenesis of systemic sclerosis. , 1996, Rheumatic diseases clinics of North America.

[10]  J. Callen,et al.  Guidelines of care for scleroderma and sclerodermoid disorders. American Academy of Dermatology. , 1996, Journal of American Academy of Dermatology.

[11]  R. Kurzrock,et al.  Combined modality therapy for cutaneous T-cell lymphoma. , 1996, Journal of the American Academy of Dermatology.

[12]  P. Lachenbruch,et al.  Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. , 1995, Arthritis and rheumatism.

[13]  R. Tigelaar,et al.  Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. , 1995, The Journal of investigative dermatology.

[14]  F. Gasparro,et al.  Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. , 1992, Journal of the American Academy of Dermatology.

[15]  S. Jimenez,et al.  Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. , 1992, Archives of dermatology.

[16]  E. Leroy,et al.  A Possible Role for Transforming Growth Factor-β in Systemic Sclerosis , 1990 .

[17]  E. Bisaccia,et al.  Photopheresis for the treatment of cutaneous T cell lymphoma. , 1990, Journal of the American Academy of Dermatology.

[18]  T. Krieg,et al.  Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. , 1990, The Journal of clinical investigation.

[19]  L. Laroche,et al.  Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). , 1989, The Yale journal of biology and medicine.

[20]  G. Littlejohn,et al.  The diagnosis and classification of scleroderma (systemic sclerosis). , 1988, Postgraduate medical journal.

[21]  K Wolff,et al.  Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. , 1987, The New England journal of medicine.

[22]  Leroy Ec,et al.  A modified scleroderma skin scoring method. , 1986 .